Program
daraxonrasib
Also written as “RMC-6236”, “Daraxonrasib” and “Daraxonrasib (Cohort B1 only)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Pancreatic Neoplasms · Colorectal Neoplasms, led by Revolution Medicines.
Furthest: phase 3, since Sep 20, 202410 company-led studies, 10 open or runningNext primary completion: May 31, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Revolution Medicines | 1010 open or running | phase 3since Sep 20, 2024 | May 13, 2022 | May 31, 2027phase 2 · NCT05379985 |
Also a collaborator on its studies: summit-therapeutics.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 13, 2022First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT05379985 · 754 planned · United States
- Nov 7, 20232 phase 2 studies in Carcinoma, Non-Small-Cell LungNCT06128551, NCT06162221
- May 20, 2024Phase 2 study in Colorectal NeoplasmsNCT06445062 · 1,130 planned · United States
- Sep 20, 2024Phase 3 study in Pancreatic NeoplasmsNCT06625320 · 500 enrolled · United States, France, Germany and more
- Mar 10, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06881784 · 590 planned · United States, Australia, Belgium and more
- Nov 13, 2025Phase 3 study in Pancreatic NeoplasmsNCT07252232 · 500 planned · United States, Canada, France and more
- Feb 2, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07397338 · 370 planned · United States
- Mar 10, 2026Phase 3 study in Pancreatic NeoplasmsNCT07491445 · 900 planned · United States, Australia, Austria and more
- Sep 1, 2026Phase 3 study in Pancreatic NeoplasmsNCT07805954 · 400 planned · United States
Ahead
- May 31, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT05379985
- Jun 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06162221
- Dec 1, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06881784
- Apr 2028Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07491445
TargetBeta
“An orally bioavailable inhibitor of the active, guanosine triphosphate (GTP)-bound form of both wild type and mutant variants of the RAS isoforms, including HRAS, NRAS and KRAS, ”NCIt, by rule
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07805954Pancreatic Neoplasms · United States | 3 | Recruiting | Mar 2029 | 400 |
| NCT07491445Pancreatic Neoplasms · United States, Australia, Austria and more | 3 | Recruiting | Apr 2028 | 900 |
| NCT07397338Carcinoma, Non-Small-Cell Lung · United States | 2 | Recruiting | May 2029 | 370 |
| NCT07252232Pancreatic Neoplasms · United States, Canada, France and more | 3 | Recruiting | May 10, 2029 | 500 |
| NCT06881784Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more | 3 | Recruiting | Dec 1, 2027 | 590 |
| NCT06625320Pancreatic Neoplasms · United States, France, Germany and more | 3 | Active, not recruiting | Jun 2026 | 500 |
| NCT06445062Colorectal Neoplasms · United States | 2 | Recruiting | Sep 30, 2028 | 1,130 |
| NCT06162221Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more | 2 | Recruiting | Jun 2027 | 616 |
| NCT06128551Carcinoma, Non-Small-Cell Lung · United States, France, Germany and more | 2 | Recruiting | Dec 2028 | 534 |
| NCT05379985Carcinoma, Non-Small-Cell Lung · United States | 2 | Recruiting | May 31, 2027 | 754 |
How it is read
Names in the registry
- “daraxonrasib”, 4 entries
- “RMC-6236”, 4 entries
- “Daraxonrasib”, 2 entries
- “Daraxonrasib (Cohort B1 only)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 5 studies
- Pancreatic Neoplasms, 4 studies
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.